Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Delivery of Pigment Epithelium Derived Factor (PEDF) To Treat Cancer by Gene Therapy Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered.
View Prospective Grant of Exclusive License: Treatment of Ocular Disease With Pigment Epithelium Derived Factor (PEDF) Protein Using Non-Gene Therapy Means Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered.
View Prospective Grant of Exclusive License: 1,8 Naphthalimide Imidazo [4,5,1-de] Acridones With Anti-Tumor Activity Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered.
View Prospective Grant of Exclusive License: Targeted Gene Expression for the Treatment of Cancer, Bone Metastasis and Diabetes Only written comments and/or applications for a license, received by the NIH Office of Technology Transfer on or before June 24, 2002, will be considered.
View Prospective Grant of Exclusive License: Synthetic Ordered Arrays of Antigen for the Induction of Autoantibodies Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 24, 2002, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Glycoprotein Hormone Superagonists Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before June 14, 2002, will be considered.
View Prospective Grant of Exclusive License: The Use of Macrocyclic Lactones as Inhibitors of Vacuolar-Type ATPases for the Treatment of Cancer Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 24, 2002, will be considered.
View Prospective Grant of Co-Exclusive License: “Cloning and Expression of cDNA for Human Dihydropyrimidine Dehydrogenase” Only written comments and/or license applications which are received by the National Institutes of Health on or before May 17, 2002, will be considered.
View Prospective Grant of Co-Exclusive License: Human Derived Monocyte Attracting Purified Peptide Products for Treating Human Infections and Neoplasms in a Human Body Only written comments and/or license applications which are received by the National Institutes of Health on or before May 13, 2002, will be considered.
View Prospective Grant of Exclusive License: Uses of Cyanovirin-N for HIV Vaccines Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 13, 2002, will be considered.
View Prospective Grant of Exclusive License: Growing Ehrlichia Species in a Continuous Cell Line 05/03/90.
View Prospective Grant of Exclusive License: Vaccines and Diagnostic Tests for Cat Scratch Fever 01/17/92.
View Prospective Grant of Exclusive License: The Use of Geldanamycin and Its Derivatives for the Treatment of Cancer Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 3, 2002, will be considered.
View Prospective Grant of Exclusive License: Gossypol, Gossypol Acetic Acid and Derivatives Thereof and the Use Thereof for Treating Cancer Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 3, 2002, will be considered.
View Prospective Grant Of Exclusive License: Prophylactic and/or Therapeutic Vaccine Against Pseudomonas aeruginosa, Chlamydia trachomatis and Mycoplasma pneumonia, Influenza virus, Nisseria gonorrhea and Vibrio cholerae Only written comments and/or applications for a license, which are received by the NIH Office of Technology Transfer on or before April 15, 2002, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Development of Diagnostic Tests for Plasmodium falciparum Caused Malaria Only written comments and/or applications for a license, which are received by the NIH Office of Technology Transfer on or before March 25, 2002, will be considered.
View Prospective Grant of Exclusive License: Specific Killing of HIV Infected Lymphocytes by a Recombinant Immunotoxin Directed Against the HIV-1 GP 120 Envelope Glycoprotein Only written comments and/or license applications which are received by the National Institutes of Health on or before March 25, 2002 will be considered.
View Prospective Grant of Co-Exclusive License: “cDNA for Human and Pig Dihydropyrimidine Dehydrogenase' Only written comments and/or license applications which are received by the National Institutes of Health on or before March 4, 2002 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant Of Exclusive License: Prophylactic and/or Therapeutic Vaccines Against HIV and HCV Only written comments and/or applications for a license which are received by NIH on or before February 4, 2002 will be considered.
View National Cancer Institute: PEGylation of Cyanovirin-N for Use in Treating Infectious Diseases Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably two pages or less, must be submitted to the NCI within 30 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Human Derived Monocyte Attracting Purified Peptide Products for Treating Human Infections and Neoplasms in a Human Body Only written comments and/or license applications which are received by the National Institutes of Health on or before January 28, 2002 will be considered.
View Government-Owned Inventions; Availability for Licensing: Method of Treating HIV With 2′, 3′-Dideoxyinosine (ddI; didanosine)